BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Open Access
- 1 July 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (1), 319-327
- https://doi.org/10.1182/blood-2005-07-2815
Abstract
Mutations in the BCR/ABL kinase domain play a major role in resistance to imatinib mesylate (IM). We report here that BCR/ABL kinase stimulates reactive oxygen species (ROS), which causes oxidative DNA damage, resulting in mutations in the kinase domain. The majority of mutations involved A/T→G/C and G/C→A/T transitions, a phenotype detected previously in patients, which encoded clinically relevant amino acid substitutions, causing IM resistance. This effect was reduced in cells expressing BCR/ABL(Y177F) mutant, which does not elevate ROS. Inhibition of ROS in leukemia cells by the antioxidants pyrrolidine dithiocarbamate (PDTC), N-acetylcysteine (NAC), and vitamin E (VE) decreased the mutagenesis rate and frequency of IM resistance. Simultaneous administration of IM and an antioxidant exerted better antimutagenic effect than an antioxidant alone. Therefore, inhibition of ROS should diminish mutagenesis and enhance the effectiveness of IM. (Blood. 2006;108:319-327)Keywords
This publication has 69 references indexed in Scilit:
- A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancerNature Genetics, 2005
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences of the United States of America, 2005
- Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLBlood, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinaseBiochemical and Biophysical Research Communications, 2004
- The biology of CML blast crisisBlood, 2004
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase βOncogene, 1999
- A table for the estimation of the spontaneous mutations rate of cells in cultureMutation Research - Reviews in Mutation Research, 1973